31 published articles
The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, and 7-5 for MOTS-c — overriding staff's negative briefing documents. The vote is non-binding; formal rulemaking must follow. Retatrutide was not evaluated under this framework: it is advancing toward a 2027 BLA filing on Phase 3 RCT data.
As of mid-2026, no completed randomized controlled trial has evaluated BPC-157 in any acute human muscle injury indication. The musculoskeletal efficacy record is entirely preclinical. One Phase 2 RCT — NCT07437547, targeting acute grade II hamstring strain — is recruiting, with co-primary endpoints of MRI-assessed injury volume at Day 14 and time to return to unrestricted sport.
Cone snail venom peptides — principally μ-, ω-, and α-conotoxin classes — reduce inflammation-induced pain in vivo through at least three mechanistically distinct pathways: voltage-gated sodium channel (NaV1.7/NaV1.8) blockade that silences peripheral nociceptor firing, N-type calcium channel (CaV2.2) inhibition that curtails spinal neurotransmitter release, and suppression of the NF-κB/COX-2 axis that drives prostaglandin-mediated peripheral sensitisation.
VRB-103 is a once-weekly oral amylin analog entering Phase 1 development by Verdiva Bio, with first-patient dosing confirmed in late July 2026. Whether it reproduces injectable-style weight-loss efficacy depends on three unresolved variables: oral bioavailability at therapeutically relevant concentrations, retention of AMY receptor selectivity after structural modification, and a tolerability profile that improves on pramlintide's nausea burden.
As of mid-2026, TB-500's wound-healing evidence base is mechanistically coherent and preclinically robust, but no completed human randomised controlled trial has evaluated the compound in any wound-healing indication. The July 2026 FDA PCAC review identified this absence as the definitive barrier to 503A compounding eligibility. The human trial gap is not narrowing — it remains structurally unbridged.
The TRIUMPH-1 topline readout — the primary obesity-without-diabetes arm of retatrutide's phase III programme — reports mean body-weight reductions of approximately 19% at 4 mg, 24% at 8 mg, and 28% at 12 mg over 80 weeks versus placebo. Cardiometabolic endpoints show dose-proportional improvements. The 80-week timepoint is the longest placebo-controlled pharmacological weight-loss dataset for any triple agonist in 2026.
Both GIPR agonism and GIPR antagonism reduce body weight in preclinical models, creating a pharmacological paradox unresolved as of 2026. GIPR agonism in hypothalamic neurons suppresses food intake, while GIPR antagonism in peripheral adipose tissue blocks lipid storage. Tirzepatide's clinical success as a GIPR agonist does not invalidate the antagonist data — it reflects a different mechanistic axis.
Phase II data for sonefpeglutide — a long-acting GLP-1/GIP/glucagon triple receptor co-agonist — demonstrate clinically meaningful reductions in hepatic steatosis, NAS score components, and fibrosis stage in biopsy-confirmed MASH. MRI-PDFF liver-fat reduction exceeded 50% relative from baseline at the highest doses, and a substantial proportion of participants achieved MASH resolution without fibrosis worsening, meeting the FDA's accepted surrogate histological endpoint.
As of 2026, oral GLP-1 receptor agonism has Phase 3 RCT evidence supporting its efficacy in obesity. Oral semaglutide 50 mg achieves 15 to 17 percent body-weight reduction, matching the 14·9 percent benchmark of subcutaneous semaglutide 2·4 mg, while orforglipron reached approximately 16 percent in Phase 3 ATTAIN-1. Neither oral agent has matched tirzepatide's approximately 20 percent ceiling.
As of mid-2026, retatrutide's TRIUMPH phase 3 programme has delivered 72-week data confirming weight reductions exceeding 20% at the 12 mg dose — the largest placebo-controlled pharmacological weight-loss signal in a completed RCT. Cardiometabolic endpoints show meaningful improvements in blood pressure, triglycerides, and glycaemic markers. Dose-limiting adverse events are predominantly gastrointestinal and concentrated in the escalation phase.
The FDA's 2026 PCAC actions against BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax reflect regulatory process — not clinical validation or invalidation. All five compounds were evaluated under the 503A Bulks List framework, which requires human safety and efficacy data that none of them possesses. The regulatory outcome maps to an evidence gap, not a clinical verdict.
The 2025 SURMOUNT-5 RCT established that tirzepatide produced approximately 20% mean body-weight reduction versus approximately 14% with semaglutide 2.4 mg over 72 weeks. Comparative cardiometabolic data show superior glycaemic control and lipid remodelling with dual agonism. Cardiovascular event data remain largely observational and directionally mixed in 2026.